Fulgent Genetics, Inc. - Common Stock (FLGT)

Fulgent Genetics exceeded expectations in the fourth quarter of 2024, showcasing robust revenue growth and a GAAP loss.

FLGT stock results show that Fulgent Genetics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.

Digital health stocks are becoming increasingly relevant as more and more people seek greater control over their health.

Fulgent Genetics Inc (NASDAQ: FLGT) reported Q2 sales of $68 million, beating the consensus estimate of $62.68 million.<

Companies Reporting Before The Bell • Arcutis Biotherapeutics (NASDAQ:ARQT) is expected to report quarterly loss at $0.86 per share on revenue of $32.83 million.

Companies Reporting Before The Bell • WPP (NYSE:WPP) is projected to report earnings for its first quarter. • Anglogold Ashanti (NYSE:AU) is likely to report earnings for its first quarter.

Fulgent is moving past its pandemic-era business, and that's a good thing.

Neither has a traditional business model, but that could be an asset for both.

Both are experiencing a bit of a hangover from declining COVID-19-related sales.

If you’re willing to take huge risks, these stocks to buy might yield you massive gains in Q2 – or you could be looking at a tax write-off.

Companies Reporting Before The Bell • CNH Industrial (NYSE:CNHI) is estimated to report quarterly earnings at $0.32 per share on revenue of $5.08 billion.

  During Friday's trading, 71 companies set new 52-week lows.

Is Vertex worth its lofty valuation compared to Invitae?

Companies that are down on their luck this year are in strong contention for conviction buys for 2023 as they rebound.